Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Operating Expenses (2016 - 2026)

Catalyst Pharmaceuticals filings provide 17 years of Operating Expenses readings, the most recent being $76.2 million for Q1 2026.

  • On a quarterly basis, Operating Expenses fell 2.43% to $76.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $329.3 million, a 8.58% increase, with the full-year FY2025 number at $331.2 million, up 11.67% from a year prior.
  • Operating Expenses hit $76.2 million in Q1 2026 for Catalyst Pharmaceuticals, down from $90.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $139.9 million in Q3 2023 to a low of $24.5 million in Q2 2022.
  • Median Operating Expenses over the past 5 years was $71.4 million (2024), compared with a mean of $66.3 million.
  • Biggest five-year swings in Operating Expenses: skyrocketed 335.18% in 2023 and later tumbled 44.39% in 2024.
  • Catalyst Pharmaceuticals' Operating Expenses stood at $30.0 million in 2022, then skyrocketed by 129.92% to $68.9 million in 2023, then increased by 14.67% to $79.0 million in 2024, then rose by 14.93% to $90.8 million in 2025, then fell by 16.1% to $76.2 million in 2026.
  • The last three reported values for Operating Expenses were $76.2 million (Q1 2026), $90.8 million (Q4 2025), and $82.1 million (Q3 2025) per Business Quant data.